Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?

Nucl Med Commun. 2011 Dec;32(12):1113-20. doi: 10.1097/MNM.0b013e32834a8341.

Abstract

Objective: This prospective observational study aimed to compare ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response with Response Evaluation Criteria In Solid Tumors (RECIST)-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of patients with advanced non-small cell lung cancer (NSCLC).

Methods: Untreated patients with advanced NSCLC scheduled to receive platinum-based chemotherapy were enrolled for this study. They underwent spiral computed tomography and ¹⁸F-fluorodeoxyglucose positron emission tomography concurrently before and after two cycles of chemotherapy. An optimal maximum standardized uptake value reduction of primary lesion was investigated retrospectively for a metabolic response.

Results: A total of 43 patients were eligible for final analysis from August 2003 to May 2007. Objective response rate (ORR) was significantly higher in RECIST-based responders compared with RECIST-based nonresponders after two cycles of platinum-based chemotherapy [85.0% (17/20) vs. 4.3% (1/23), respectively; P=0.000], but median progression-free survival (PFS) and median overall survival (OS) were similar [5.8 95% confidence interval (CI): 3.6-8.0) vs. 5.0 (95% CI: 3.3-6.7) months, respectively, P=0.761; 13.7 (95% CI: 7.3-20.1) vs. 15.5 (95% CI: 3.8-27.2) months, respectively, P=0.356]. At the optimal cut-off value (maximum standardized uptake value reduction of primary lesion by 31%) for a metabolic response after two cycles of chemotherapy, metabolic responders had a significantly higher ORR [66.7% (16/24) vs. 10.5% (2/19), P=0.000] and a longer median PFS [6.5 (95% CI: 5.2-7.8) vs. 4.8 (95% CI: 2.9-6.7) months, P=0.041]; median OS was 17.7 months (95% CI: 9.2-26.2) in metabolic responders and 12.0 months (95% CI: 3.3-20.7) in metabolic nonresponders (P=0.799).

Conclusion: Metabolic response could be superior to RECIST-based response after two cycles of platinum-based chemotherapy in predicting PFS of untreated patients with advanced NSCLC. Both of them could be predictive for ORR, but neither of them could predict OS.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Carboplatin / administration & dosage
  • Carcinoma, Non-Small-Cell Lung / diagnostic imaging*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Cisplatin / administration & dosage
  • Disease-Free Survival
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / mortality
  • Male
  • Middle Aged
  • Multimodal Imaging / methods*
  • Organoplatinum Compounds / administration & dosage
  • Positron-Emission Tomography*
  • Prognosis
  • Prospective Studies
  • Radiopharmaceuticals*
  • Retrospective Studies
  • Survival Rate
  • Tomography, Spiral Computed
  • Tomography, X-Ray Computed*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • nedaplatin
  • Carboplatin
  • Cisplatin